Paul Hesketh to Cyclophosphamide
This is a "connection" page, showing publications Paul Hesketh has written about Cyclophosphamide.
Connection Strength
0.591
-
Hesketh PJ, Crews JR, Cohen R, Blackburn LM, Friedman CJ. Antiemetic efficacy of single-dose oral granisetron (1 mg vs 2 mg) with moderately emetogenic chemotherapy. Cancer J. 2000 May-Jun; 6(3):157-61.
Score: 0.169
-
Aapro M, Jordan K, Gralla RJ, Rizzi G, Rossi G, Palmas M, Alyasova AV, Lisyanskaya AS, Bo?njak SM, Hesketh PJ. Safety and efficacy of NEPA, an oral fixed combination of netupitant and palonosetron, in older patients. J Geriatr Oncol. 2017 01; 8(1):56-63.
Score: 0.133
-
Hesketh PJ, Sanz-Altamira P. Aprepitant, dexamethasone, and palonosetron in the prevention of doxorubicin/cyclophosphamide-induced nausea and vomiting. Support Care Cancer. 2012 Mar; 20(3):653-6.
Score: 0.094
-
Hesketh PJ, Younger J, Sanz-Altamira P, Hayden M, Bushey J, Trainor B, Krentzin M, Nowd P, Arnaoutakis K, Hesketh AM. Aprepitant as salvage antiemetic therapy in breast cancer patients receiving doxorubicin and cyclophosphamide. Support Care Cancer. 2009 Aug; 17(8):1065-70.
Score: 0.077
-
Herrstedt J, Celio L, Hesketh PJ, Zhang L, Navari R, Chan A, Saito M, Chow R, Aapro M. 2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following high-emetic-risk antineoplastic agents. Support Care Cancer. 2023 Dec 21; 32(1):47.
Score: 0.054
-
Hesketh PJ, Gandara DR, Hesketh AM, Facada A, Perez EA, Webber LM, Martin LA, Cramer MB, Hahne WF. Dose-ranging evaluation of the antiemetic efficacy of intravenous dolasetron in patients receiving chemotherapy with doxorubicin or cyclophosphamide. Support Care Cancer. 1996 Mar; 4(2):141-6.
Score: 0.032
-
Warr DG, Hesketh PJ, Gralla RJ, Muss HB, Herrstedt J, Eisenberg PD, Raftopoulos H, Grunberg SM, Gabriel M, Rodgers A, Bohidar N, Klinger G, Hustad CM, Horgan KJ, Skobieranda F. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol. 2005 Apr 20; 23(12):2822-30.
Score: 0.015
-
Perez EA, Hesketh P, Sandbach J, Reeves J, Chawla S, Markman M, Hainsworth J, Bushnell W, Friedman C. Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study. J Clin Oncol. 1998 Feb; 16(2):754-60.
Score: 0.009
-
Rubenstein EB, Gralla RJ, Hainsworth JD, Hesketh PJ, Grote TH, Modiano MR, Khojasteh A, Kalman LA, Benedict CR, Hahne WF. Randomized, double blind, dose-response trial across four oral doses of dolasetron for the prevention of acute emesis after moderately emetogenic chemotherapy. Oral Dolasetron Dose-Response Study Group. Cancer. 1997 Mar 15; 79(6):1216-24.
Score: 0.008